Frank Rimerman Advisors LLC Invests $374,000 in Sanofi (NASDAQ:SNY)

Frank Rimerman Advisors LLC acquired a new stake in shares of Sanofi (NASDAQ:SNY) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 7,714 shares of the company’s stock, valued at approximately $374,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. TCTC Holdings LLC raised its position in shares of Sanofi by 28.0% during the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock valued at $47,000 after buying an additional 210 shares in the last quarter. HB Wealth Management LLC lifted its stake in Sanofi by 3.7% during the second quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock worth $299,000 after purchasing an additional 221 shares during the last quarter. Wynn Capital LLC boosted its stake in Sanofi by 4.5% in the first quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock worth $256,000 after buying an additional 226 shares in the last quarter. Angeles Investment Advisors LLC boosted its stake in shares of Sanofi by 2.1% in the 4th quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company’s stock valued at $598,000 after purchasing an additional 244 shares in the last quarter. Finally, EP Wealth Advisors LLC lifted its stake in Sanofi by 5.3% in the fourth quarter. EP Wealth Advisors LLC now owns 5,035 shares of the company’s stock worth $250,000 after purchasing an additional 255 shares during the last quarter. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Trading Up 0.3 %

NASDAQ SNY opened at $57.62 on Wednesday. The firm has a market capitalization of $145.94 billion, a PE ratio of 28.95, a P/E/G ratio of 1.62 and a beta of 0.60. The stock’s 50 day moving average is $54.64 and its 200 day moving average is $50.66. Sanofi has a twelve month low of $42.63 and a twelve month high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.95 EPS. Research analysts forecast that Sanofi will post 4.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently commented on SNY shares. Argus lifted their price objective on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, StockNews.com upgraded shares of Sanofi from a “buy” rating to a “strong-buy” rating in a report on Friday, September 20th. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Sanofi has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.